Fundraising FoxJDRF T1D Fund — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
Immunocore is a biotechnology company developing T cell receptor (TCR) based immunomodulating therapies for patients with cancer, infectious diseases, and autoimmune diseases.
BiotechHealthtechAbingdon, Oxfordshire
Brian Di Donato(Chief Financial Officer)David Berman(Head of Research and Development)inTina St. Leger(Chief Human Resources Officer)inBahija Jallal(Chief Executive Officer)inRobert Perez(Director)Peter Ratcliffe(Director)
Co-investorsAvego BioScience CapitalGeneral AtlanticRosetta Capital Ltd.
Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.
BiotechDeep TechHealthtechHatfield, US
Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)in
BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)
Co-investorsNew Enterprise Associates (NEA)4BIO CapitalAmgen VenturesHatteras Venture PartnersNorthpond VenturesTakeda Ventures+1 more
Kriya provides working capital loans and business finance products to UK and European businesses, helping them manage cash flow, fund wholesale orders, and scale their buyer base.
FintechSaaS
Anil Stocker(Founder)inCharles Delingpole(Founder)Ilya Kondrashov(Founder)
Co-investorsMouro CapitalNorthzoneBluebird VenturesForesite CapitalHolland CapitalNarya Capital+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.